

Pulmonary Uptake of Tc-99m-Labeled Methylene Diphosphonate in a Patient with a Parathyroid Adenoma

J. Y. Herry, D. Chevet, A. Moisan, P. Le Pogamp, J. J. Le Jeune, and Y. Kerdiles

Hôpital de Pontchaillou, Rennes, France

Intense diffuse uptake of Tc-99m-labeled methylene diphosphonate was seen in both lungs of a patient submitted to surgery for a primary parathyroid adenoma. Five scans performed over the 3 yr following the operation showed persistence of lung uptake despite restoration of normal blood calcium concentration. Mild chronic renal failure caused by the hypercalcemia also persisted postoperatively. The present case confirms that pulmonary uptake of a bone tracer can occur asymptotically when both hypercalcemia and renal failure are present. Lung uptake of a bone tracer probably reflects tissue deposition of hydroxyapatite rather than of amorphous structures. Correction of the hypercalcemia failed to resolve the abnormal scan pictures.

J Nucl Med 22: 888-890, 1981

Over recent years bone imaging with technetium-labeled tracers has gained increasing acceptance for the diagnosis and follow-up of many bone and joint diseases. Several reports of unusual soft-tissue uptake patterns have appeared (1-8). In our medical center, where approximately 7,000 bone scans have been performed, three patients have been seen with pulmonary uptake of Tc-99m-labeled methylene diphosphonate (Tc-99m MDP). Uptake was focal in two of the patients, but bilateral and diffuse in the third patient, who had a primary parathyroid adenoma. The present report concerns this third patient, in whom pulmonary images were followed over the 3 yr following removal of the tumor. A total of five anterior and posterior scans were performed with a total-body imager, 3 hr after the injection of 15 mCi of Tc-99m MDP.

CASE REPORT

The patient was a 63-yr-old woman. The only noteworthy feature of her history was childhood poliomyelitis, which had left her with paralysis of the left arm. During her first hospital admission in 1975 for digestive disorders, gallstones were discovered and a cholecystectomy was performed. The patient was anemic at this time but no cause could be found. Renal function was normal. Her condition deteriorated and she was admitted again in 1977. A diagnosis of renal failure associated with hypercalcemia was established (Table 1). On physical examination a palpable nodule was noticed in the neck. Blood pressure was 135/70 and pulse 86. Radiography showed osteodystrophy of the skull, and subperiosteal resorption in the phalanges. An i.v. urogram revealed a calcine stone in the left kidney with no evidence of nephrocalcinosis. Chest

radiograph was normal, as was blood gas analysis: blood pO_2 96 mm Hg; blood pCO_2 36 mm Hg; oxyhemoglobin saturation 95%; plasma pH 7.4; arterial whole-blood CO_2 content 23 mmol/l. Tc-99m MDP scanning showed increased uptake in the skull but no other skeletal changes. Diffuse radioactivity was noted in both lungs (Fig. 1). Because of an elevated plasma parathyroid-hormone level and increased urinary cAMP excretion, exploratory surgery of the neck was done. A single parathyroid tumor, weighing 10.7 g, was removed. The other three glands were normal. Histologic examination confirmed that the tumor was an adenoma. Microscopically, a bone fragment removed from the iliac crest at operation showed numerous, large spaces around osteocytes, and increased osteoclast resorption.

Following operation the clinical course has been uneventful, with no sign of major disease. The patient leads a normally active life. Blood calcium concentration returned to normal (2.21 mmol/l) and has remained so in the absence of any subsequent therapeutic measures. A mild renal failure persists but has stabilized (Table 1). Five repeat scans, performed over a 3-yr period, have shown persistent diffuse pulmonary uptake with no pronounced change in density (Fig. 1).

DISCUSSION

In the present case, a diagnosis of primary parathyroid adenoma could be established with certainty on the strength of the operative findings, the cell structure in the bone, and the subsequent course. Postoperative persistence of mild renal failure is not a rare occurrence in cases such as this. The parathyroid hormone level did not return to normal postoperatively owing to the secondary parathyroid hyperplasia caused by the chronic renal failure itself. The main interest of this case is the finding of strikingly intense diffuse uptake of Tc-99m MDP in both lungs, a finding all the more remarkable in that there were no clinical or radiographic

Received Feb. 2, 1981; revision accepted May 15, 1981.

For reprints contact: Docteur J. Y. Herry, Chef de Travaux, Assistant des Hôpitaux, Département des Radioisotopes, Centre Eugène Marquis, C.H.R. de Pontchaillou, 35011 Rennes Cedex, France.

TABLE 1. BIOCHEMICAL FINDINGS

	Normal	Before operation	After operation				
			2 mo	6 mo	9 mo	20 mo	36 mo
Calcium (mmol/l)	2.35–2.65	3.9	2.21	2.47	2.47	2.55	2.36
Phosphates (mmol/l)	0.80–1.45	1.18	1.15	1.28	1.18	1.26	0.87
Creatinine (μ mol/l)	50–110	203	150	150	115	119	117
Creatinine clearance (ml/min)	75–126	28	—	39	—	48	43
TRP (%)	\geq 85	55	—	83	—	—	81
Parathyroid hormone (U/l)	1.11–3.79	7.6	—	—	—	—	5.41

abnormalities nor changes in blood-gas data. Lung biopsy was not felt to be warranted, since the abnormal scanning picture was an isolated finding and since respiratory function was normal. A diagnosis of pulmonary metastatic calcification was held likely in the light of data reported in the literature.

Two cases of parathyroid adenoma with bilateral pulmonary uptake of a technetium-labeled diphosphonate tracer have been reported (9,10). In both cases hypercalcemia and renal failure were present, but unfortunately the outcome was rapidly fatal and no follow-up studies could be done. Autopsy revealed diffuse pulmonary microcalcifications that had escaped radiographic detection. The present case sheds more light on the problem raised by these two cases in that for the first time the subsequent outcome of diffuse lung uptake could be observed in a patient after removal of a parathyroid adenoma.

Pulmonary uptake has been reported in a case of breast cancer

with multiple bony metastases described by Watson (11), but in this case the uptake images disappeared after correction of hypercalcemia. In the present case, restoration of normal blood calcium was not accompanied by resolution of the metastatic calcification. One possible explanation for the abnormally persistent lung images could be the chronic renal failure. Indeed, pulmonary calcifications have been found at autopsy in 60 to 75% of patients with chronic renal failure (12,13), and in many of these cases the calcifications had produced no clinical or radiologic signs before the patient's death. The absence of radiologic abnormalities in the present case, therefore, is not surprising. Even with bone-seeking radiopharmaceuticals, metastatic calcifications in uremic patients are not consistently detected (14,15). This could be because, as Conger has shown (16), technetium-labeled bone tracers have poor affinity for amorphous visceral calcifications. As this same investigator has shown, however, they do have extremely high affinity for hydroxyapatite crystals. There is one clinical situation in which, as de Graaf has suggested, hydroxyapatite crystals might form in the lung: it occurs when hypercalcemia coexists with renal failure. In this respect, it is interesting that most reported cases of diffuse lung uptake of a bone tracer—whatever the underlying disease—feature the coexistence of renal failure and hypercalcemia (9). A scanning picture of diffuse lung uptake, therefore, is not specific to hyperparathyroidism and does not obviate the need for exploratory surgery of the neck in patients with suspected parathyroid adenoma. Nor, as the present case shows, is such a picture necessarily accompanied by respiratory failure, nor is the outcome necessarily fatal, as it can be in cases of pulmonary calcification due to calciphylaxis seen in patients with chronic renal failure (17).

REFERENCES

1. GRAMES GM, SAUSER DD, JANSEN C, et al: Radionuclide detection of diffuse interstitial pulmonary calcification. *JAMA* 230:992–995, 1974
2. MC LAUGHLIN AF: Uptake of ^{99m}Tc bone-scanning agent by lungs with metastatic calcification. *J Nucl Med* 16: 322–323, 1975
3. RICHARDS AG: Metastatic calcification detected through scanning with ^{99m}Tc polyphosphate. *J Nucl Med* 15:1057–1060, 1974
4. MOINUDDIN M, ROCKETT JF, WEBER A: Scanning for pulmonary calcification. *Ann Int Med* 84:224, 1976 (Letter to the Editor)
5. BROWER AC, TEATES CD: Positive ^{99m}Tc polyphosphate scan in case of metastatic osteogenic sarcoma and hypertrophic pulmonary osteoarthropathy. *J Nucl Med* 15:53–55, 1974
6. BROWN ML, SWEE RG, OLSON RJ, et al: Pulmonary uptake of ^{99m}Tc diphosphonate in alveolar microlithiasis. *Am J Roentgenol* 131:703–704, 1978




FIG. 1. Bone scans 3 hr after injection of 15 mCi of Tc-99m MDP. Scan No. 1 was performed 10 days before removal of a parathyroid adenoma; scan no. 2, 3 yr after operation. Dense diffuse uptake is seen in both lungs in the two scans. (Left arm was paralyzed by polio.)

7. BEIN ME, LEE DBN, MINK JH, et al: Unusual case of metastatic pulmonary calcification. *Am J Roentgenol* 132: 812-816, 1979
8. KIM EE, DOMSTAD PA, CHOY YC, DELAND FH: Accumulation of Tc-99m phosphonate complexes in metastatic lesions from colon and lung carcinomas. *Eur J Nucl Med* 5: 299-301, 1980
9. ROSENTHAL DI, CHANDLER HL, AZIZI F, et al: Uptake of bone imaging agents by diffuse pulmonary metastatic calcification. *Am J Roentgenol* 129:871-874, 1977
10. ST GOAR WT, GALLAGHER MJ: Case records of the Massachusetts General Hospital: severe hypercalcemia with a fulminant course in a 52-year-old woman. *N Engl J Med* 295:433-440, 1976
11. WATSON NW, COWAN RJ, MAYNARD CD, et al: Resolution of metastatic calcification revealed by bone scanning: Case report. *J Nucl Med* 18:890-892, 1977
12. CONGER JD, HAMMOND WS, ALFREY AC, et al: Pulmonary calcification in chronic dialysis patients. Clinical and pathologic studies. *Ann Int Med* 83:330-336, 1975
13. KUZELA DC, HUFFER WE, CONGER JD, et al: Soft tissue calcification in chronic dialysis patients. *Am J Pathol* 86: 403-424, 1977
14. DE GRAAF P, SCHICHT IM, PAUWELS EKJ, et al: Bone scintigraphy in uremic pulmonary calcification. *J Nucl Med* 20:201-206, 1979
15. ØLGAARD K, HEERFORDT J, MADSEN S: Scintigraphic skeletal changes in uremic patients on regular hemodialysis. *Nephron* 17:325-334, 1976
16. CONGER JD, ALFREY AC: Reply to letter to the editor. *Ann Int Med* 84:224-225, 1976
17. JUSTRABO E, GENIN R, RIFLE G: Pulmonary metastatic calcification with respiratory insufficiency in patients on maintenance haemodialysis. *Thorax* 34:384-388, 1979

THIRD WORLD CONGRESS OF NUCLEAR MEDICINE AND BIOLOGY
Sponsored by the World Federation of Nuclear Medicine and Biology

August 29-September 2, 1982

Palais des Congrès

Paris, France

Call for Abstracts for Scientific Program

The WFNMB welcomes the submission of abstracts of scientific papers for either oral or poster presentation at the Third World Congress of Nuclear Medicine and Biology, which will convene at the Palais des Congrès in Paris, France, August 29 - September 2, 1982. Original contributions may be submitted on several topics, as follows:

<p>Radiopharmaceuticals Cyclotron isotopes Reactor isotopes Technetium Generators</p> <p>Radioimmunoassay Production, quality control Applications in neonatology, endocrinology, or oncology Automation</p>	<p>Clinical Applications Cardiology Endocrinology Nephrology Pulmonary diseases Gastroenterology Neurology Bone and joint Hematology Metabolism Electrolytes Therapy Pediatrics</p>	<p>Instrumentation Detectors Electronics Data processing and display Tomographic techniques</p> <p>Nuclear and Non-Nuclear Investigations Ultrasound Computerized tomography Nuclear magnetic resonance Autoradiography and subcellular localization</p> <p>Radiobiology, Health Physics, Dosimetry</p> <p>Economics and Management</p>
---	--	---

Abstracts selected for the Scientific Program, whether for oral or poster presentation, will be published in the Congress Proceedings and distributed to all attendees on site.

The official language is English and some facilities for simultaneous translation will be available.

Abstracts must be submitted on the official abstract form, which may be obtained by calling or writing either of the addresses listed below:

Society of Nuclear Medicine
 Att: WFNMB Abstracts
 475 Park Avenue South
 New York, NY 10016
 Tel: (212)889-0717

WFNMB
 B.P. 28
 F 91403 Orsay
 France
 Tel: (6) 928.55.74

Abstracts must be received in Paris by no later than Tuesday, December 1, 1981